Prospective External Validation of the HFA-ICOS Baseline Cardiovascular Risk Classification in Women with Breast Cancer Receiving Anthracycline-Containing Therapy in a Central Asian Cohort
Authors:
- Aiganym AmanovaAAAiganym Amanova
- Bekbolat ZholdinBZBekbolat Zholdin
- Saule BalmagambetovaSBSaule Balmagambetova
- Iliada TalipovaITIliada Talipova
- Gulnara KurmanalinaGKGulnara Kurmanalina
- Saule MadinovaSMSaule Madinova
- Mira BaspayevaMBMira Baspayeva
- Kulparshan KubenovaKKKulparshan Kubenova
- Gulmira SultanbekovaGSGulmira Sultanbekova
- Maria PoltavskayaMPMaria Poltavskaya
- Zhenisgul TlegenovaZTZhenisgul Tlegenova
Open Access
- 17 October 2026
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3379
Abstract
Background/Objectives: The HFA-ICOS baseline cardiovascular risk classification was developed to standardize pretreatment risk stratification before potentially cardiotoxic cancer therapy, but its external performance across diverse populations remains incompletely characterized. We prospectively evaluated its performance in women with breast cancer receiving anthracycline-containing therapy in Central Asia. Methods: This prospective single-center external validation study used data from the PREDICATE cohort (ISRCTN12628444). Participants were classified at baseline as being at low, moderate, high, or very high cardiovascular risk according to the HFA-ICOS classification before treatment and outcome ascertainment; the high- and very-high-risk categories were pooled for analysis because of small numbers. Participants underwent serial cardiovascular surveillance, including echocardiographic assessment of left ventricular ejection fraction and global longitudinal strain, together with serial cardiac biomarker measurements. The primary outcome was cancer therapy-related cardiac dysfunction (CTRCD), defined according to the 2022 ESC cardio-oncology criteria. Results: The analysis included 108 participants. CTRCD occurred in 43 of 108 participants (39.8%). The observed proportion of participants who developed CTRCD increased from 30.0% in the low-risk group to 47.5% in the moderate-risk group and 75.0% in the high/very-high-risk group (p = 0.026). Kaplan–Meier analysis demonstrated significant separation of CTRCD-free survival across HFA-ICOS risk categories (log-rank χ2 = 10.12; p = 0.006). Compared with the low-risk group, the hazard of CTRCD was higher in the moderate-risk group (hazard ratio [HR], 2.16; 95% confidence interval [CI], 1.13–4.13) and high/very-high-risk group (HR, 3.59; 95% CI, 1.42–9.11). Discrimination was modest (area under the curve, 0.630; 95% CI, 0.530–0.724). Conclusions: The HFA-ICOS classification demonstrated a clear ordinal gradient in CTRCD risk and significant time-to-event separation but showed limited discrimination at the individual-patient level. It may guide initial risk stratification but should be complemented by longitudinal cardiovascular surveillance rather than used as a stand-alone predictor.Keywords
Funding Information
- West Kazakhstan Marat Ospanov Medical University (AP09259524)
- West Kazakhstan Marat Ospanov Medical University (0121PK00565)
- West Kazakhstan Marat Ospanov Medical University (ISRCTN12628444)
This publication has 56 references indexed in Scilit:
- Practical guidance for echocardiography for cancer therapy-related cardiac dysfunction: 2026 focused updateJournal of Echocardiography, 2026
- Heart Failure with Preserved Ejection Fraction in Cancer Patients and Survivors. A Scientific Statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-OncologyEuropean Journal of Heart Failure, 2025
- World Medical Association Declaration of HelsinkiJAMA, 2025
- Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Minimum sample size calculations for external validation of a clinical prediction model with a time‐to‐event outcomeStatistics in Medicine, 2021
- Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)European Journal of Heart Failure, 2020
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA–PEFF Diagnostic Algorithm: A Consensus Recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)European Journal of Heart Failure, 2020
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendationsAnnals of Oncology, 2020
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular riskAtherosclerosis, 2019